A Pharmacokinetic Evaluation of Metformin in Relation to the Polymorphism A270S in Healthy Caucasian Volunteers

A Pharmacokinetic Evaluation of Metformin in Relation to the Polymorphism A270S in Healthy Caucasian Volunteers.

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01237522

Enrollment

Registered

2010-11-09

Start date

2010-08-31

Completion date

2010-12-31

Last updated

2010-12-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Metformin, Organic Cation Transporter 2, Polymorphism,Single Nucleotide

Keywords

Diabetes Mellitus, Type 2, Metabolic Clearance Rate, Pharmacokinetics, Pharmacogenetics

Brief summary

The aim of the study is to evaluate the pharmacokinetics of metformin in healthy Caucasians volunteers with and without the polymorphism A270S in OCT2,thus the study hypothesis is that renal clearance of metformin is affected in Caucasian with the known single nucleotide polymorphisms A270S in OCT2.

Interventions

DRUGMetformin

A single dose study with one tablet of metformin 500 mg, time frame 24 hours

Study design

Allocation

NON_RANDOMIZED

Intervention model

PARALLEL

Primary purpose

HEALTH_SERVICES_RESEARCH

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 65 Years

Healthy volunteers

Yes

Inclusion criteria

* Healthy volunteers * Written consent * rs316019 genotyped * Age 18-65 years old

Exclusion criteria

* Daily medication * Alcohol abuse * Pregnancy * Breastfeeding

Design outcomes

Primary

Measure	Time frame
Renal clearance of metformin	24 Hours

Countries

Denmark

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026